drug

INCA33890

1 story · latest Sep 16, 2026

Status: Investigational
Trials: 4 registered trials in coverage

Relationships

Developed by Incyte Corporation

Timeline

Incyte registers Phase 2 trial of INCA33890 in MRD-positive colorectal cancer

Sep 16Trial updateINCA33890 Incyte Corporation

Biotech intelligence from primary sources. Every story is an original summary of a public record, linked to its source. Not investment advice.

Terms Privacy hello@readthrough.news

readthrough is a product of JAMN Ventures, LLC.